Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic fecal microbiota
- Development stage
- Approved
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal, Nasogastric, Nasoduodenal, Intraduodenal
01
Overview
Allogeneic fecal microbiota is a therapeutic approach that involves transplanting fecal matter from a healthy donor into the gastrointestinal tract of a recipient to restore gut microbiota diversity and function. The procedure directly modifies the host gut microbiome composition to restore diversity and gut homeostasis. It can be delivered via various routes including the upper gastrointestinal tract (using esophagogastroduodenoscopy, nasogastric or nasoduodenal tube, oral capsule) or lower gastrointestinal tract (via colonoscopy or enema). The source of fecal material is from a related or unrelated healthy donor (allogeneic), as opposed to autologous FMT where the patient's own previously collected stool is used.
- Brand names
- REBYOTAVOWST
- Other names
- FMTfecal microbiota transplantationfecal microbiota transferstool transplantbacteriotherapyintestinal microbiota transplantfecal microbiota live-jslm
Beyond the preview
Go deeper on allogeneic fecal microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic fecal microbiota.